AI
DNTH icon

Allostery Investments’s Dianthus Therapeutics DNTH Stock Holding History

Allostery Investments’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,000
Closed -$545K – 45
2024
Q4 		$545K Buy
+25,000
New +$643K 0.57% 27

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Allostery Investments's DNTH Position: Q1 2025 in Review

Allostery Investments sold out of Dianthus Therapeutics (DNTH) in Q1 2025, closing a stake of 25,000 shares — an estimated $545K sold.

Allostery Investments first reported a position in DNTH in Q4 2024 and held it in 1 quarter. The position peaked at $545K in Q4 2024. 98 funds tracked by Wall St. Rank hold DNTH as of Q1 2025.

  • Allostery Investments reported no remaining Dianthus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Allostery Investments sold 25,000 Dianthus Therapeutics shares in Q1 2025, an estimated $545K.
  • Allostery Investments first reported a position in Dianthus Therapeutics in Q4 2024 and held it in 1 quarter.
  • Allostery Investments's Dianthus Therapeutics position peaked at $545K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2025.

Based on Allostery Investments's 13F filing for Q1 2025, filed 15 May 2025.